Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Aspirin  COVID-19 treatment studies for Aspirin  C19 studies: Aspirin  Aspirin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 46% Improvement Relative Risk c19early.org/e Karruli et al. Aspirin for COVID-19 ICU PATIENTS Is very late treatment with aspirin beneficial for COVID-19? Retrospective 32 patients in Italy (March - May 2020) Study underpowered to detect differences Karruli et al., Microbial Drug Resistance, doi:10.1089/mdr.2020.0489 Favors aspirin Favors control
Multidrug-Resistant Infections and Outcome of Critically Ill Patients with Coronavirus Disease 2019: A Single Center Experience
Karruli et al., Microbial Drug Resistance, doi:10.1089/mdr.2020.0489
Karruli et al., Multidrug-Resistant Infections and Outcome of Critically Ill Patients with Coronavirus Disease 2019: A Single.., Microbial Drug Resistance, doi:10.1089/mdr.2020.0489
Sep 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 32 ICU patients showing lower mortality with aspirin treatment, without statistical significance.
risk of death, 46.3% lower, RR 0.54, p = 0.63, treatment 1 of 5 (20.0%), control 22 of 27 (81.5%), NNT 1.6, adjusted per study, odds ratio converted to relative risk, multivariable.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Karruli et al., 1 Sep 2021, retrospective, Italy, peer-reviewed, 13 authors, study period March 2020 - May 2020.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperAspirinAll
Abstract: MICROBIAL DRUG RESISTANCE Volume 27, Number 9, 2021 ª Mary Ann Liebert, Inc. DOI: 10.1089/mdr.2020.0489 Multidrug-Resistant Infections and Outcome of Critically Ill Patients with Coronavirus Disease 2019: A Single Center Experience Arta Karruli,1 Filomena Boccia,1 Massimo Gagliardi,1 Fabian Patauner,1 Maria Paola Ursi,1 Pino Sommese,1 Rosanna De Rosa,2 Patrizia Murino,2 Giuseppe Ruocco,3 Antonio Corcione,2 Roberto Andini,4 Rosa Zampino,4,5 and Emanuele Durante-Mangoni1,4 Background: The aim of this study was to assess the drivers of multidrug-resistant (MDR) bacterial infection development in coronavirus disease 2019 (COVID-19) and its impact on patient outcome. Methods: Retrospective analysis on data from 32 consecutive patients with COVID-19, admitted to our intensive care unit (ICU) from March to May 2020. Outcomes considered were MDR infection and ICU mortality. Results: Fifty percent of patients developed an MDR infection during ICU stay after a median time of 8 [4–11] days. Most common MDR pathogens were carbapenem-resistant Klebsiella pneumoniae and Acinetobacter baumannii, causing bloodstream infections and pneumonia. MDR infections were linked to a higher length of ICU stay ( p = 0.002), steroid therapy ( p = 0.011), and associated with a lower ICU mortality (odds ratio: 0.439, 95% confidence interval: 0.251–0.763; p < 0.001). Low-dose aspirin intake was associated with both MDR infection ( p = 0.043) and survival ( p = 0.015). Among MDR patients, mortality was related with piperacillintazobactam use ( p = 0.035) and an earlier onset of MDR infection ( p = 0.042). Conclusions: MDR infections were a common complication in critically ill COVID-19 patients at our center. MDR risk was higher among those dwelling longer in the ICU and receiving steroids. However, MDR infections were not associated with a worse outcome. Keywords: MDR, COVID-19, SARS-CoV-2, ICU, outcome
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit